文献速递胸部肿瘤

2019年肺癌PD-L1检测:IASLC病理委员会视角

PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee.
PubMed 文献 · J Thorac Oncol · 2019-12-20

IASLC病理委员会综述了2019年肺癌免疫检查点抑制剂适应症及PD-L1免疫组化检测的分析前、分析及分析后关键问题,包括标本类型、检测验证、外部质量保证和培训,强调PD-L1作为预测生物标志物的正确实施与判读具有挑战性。

要点

  • 部分PD-L1免疫组化检测已验证用于对应药物一线或二线治疗处方。
  • 许多实验室采用内部或实验室自建检测,较临床试验验证的昂贵检测更可负担。
  • PD-L1免疫组化检测的适当实施与判读因多种抗体克隆、平台或检测及样本通常较小而具有挑战性。

核心结论

  • PD-L1免疫组化检测作为预测生物标志物,其适当实施与判读至关重要且可能具有挑战性。

研究设计与样本

  • IASLC病理委员会综述,基于自IASLC肺癌PD-L1免疫组化检测图谱发布以来发表的许多文章。

主要发现

  • 多个免疫检查点抑制剂临床试验通过免疫组化评估肿瘤细胞和肿瘤浸润免疫细胞中PD-L1蛋白表达的预测价值,应用了特定免疫组化平台的不同检测。
  • 部分PD-L1免疫组化检测已验证用于对应药物一线或二线治疗处方。
  • 并非所有实验室配备专用平台,许多实验室建立了内部或实验室自建检测,较临床试验验证的昂贵检测更可负担。

临床怎么用

  • PD-L1免疫组化检测已在大多数病理实验室部署,需关注分析前、分析及分析后方面,包括标本类型、检测验证、外部质量保证和培训。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The recent development of immune checkpoint inhibitors (ICIs) has led to promising advances in the treatment of patients with NSCLC and SCLC with advanced or metastatic disease. Most ICIs target programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) axis with the aim of restoring antitumor immunity. Multiple clinical trials for ICIs have evaluated a predictive value of PD-L1 protein expression in tumor cells and tumor-infiltrating immune cells (ICs) by immunohistochemistry (IHC), for which different assays with specific IHC platforms were applied. Of those, some PD-L1 IHC assays have been validated for the prescription of the corresponding agent for first- or second-line treatment. However, not all laboratories are equipped with the dedicated platforms, and many laboratories have set up in-house or laboratory-developed tests that are more affordable than the generally expensive clinical trial-validated assays. Although PD-L1 IHC test is now deployed in most pathology laboratories, its appropriate implementation and interpretation are critical as a predictive biomarker and can be challenging owing to the multiple antibody clones and platforms or assays available and given the typically small size of samples provided. Because many articles have been published since the issue of the IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer, this review by the IASLC Pathology Committee provides updates on the indications of ICIs for lung cancer in 2019 and discusses important considerations on preanalytical, analytical, and postanalytical aspects of PD-L1 IHC testing, including specimen type, validation of assays, external quality assurance, and training.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Lantuejoul S, Sound-Tsao M, Cooper WA, et al. PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. J Thorac Oncol. 2019. PMID: 31870882. doi:10.1016/j.jtho.2019.12.107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。